Browse the evidence

Post-exercise cooling (e.g., cold water immersion) applied in the early recovery phase (< 1 hour) improves fatigue resistance following endurance exercise in hot conditions and may enhance maximal strength recovery after resistance exercise.

If you train in the heat or do heavy lifting, a 10-30 minute cold water immersion (5-20°C) immediately after your session can help you recover strength and fatigue resistance faster. However, avoid this if you just did sprint intervals, as it may hurt your power output for the next session.

Single application of cooling has generally no effect on recovery during the 24–72 hour period following resistance and endurance exercises, though it may benefit neuromuscular function recovery 24–48 hours after sprint exercise.

If you have a competition or hard workout 24-72 hours later, cold water immersion after your initial session won't significantly help you recover from resistance or endurance training. It might help if you did sprint intervals, but don't rely on it for general late recovery.

Triple agonists (retatrutide, SAR441255) demonstrate superior efficacy in reversing fatty liver disease (MASH) compared to dual agonists and GLP-1 monotherapy.

For those with fatty liver disease (MASH), triple agonists like retatrutide have shown remarkable ability to normalize liver fat in 90% of patients in clinical trials. This makes them a promising treatment option for liver health, beyond just weight loss.

During pandemic lockdown, individuals previously engaged in resistance training maintained participation rates (82.8%) but adapted their training location to home, shifted to bodyweight exercises, and reduced perceived effort, resulting in lower perceived effectiveness and enjoyment.

If you are used to training in a gym, do not stop training when you cannot access it. Shift to bodyweight exercises or home equipment, and accept that your perceived effort and enjoyment might drop temporarily. Focus on maintaining the habit of training 2-3 times per week rather than perfecting the routine or intensity. Your body will adapt, and you can gradually reintroduce complexity as access allows.

GLP-1 receptor agonists (Liraglutide and Exenatide) significantly improve menstrual frequency and ovulation rates in overweight/obese women with PCOS, primarily through weight loss and insulin resistance reduction rather than direct ovarian stimulation.

For overweight women with PCOS struggling with irregular periods, GLP-1 agonists like Liraglutide or Exenatide (often combined with Metformin) are effective treatments. They improve menstrual regularity and ovulation rates significantly better than Metformin alone. The benefits are largely driven by weight loss and reduced insulin resistance, but may also involve direct hormonal regulation. Consult a doctor for dosing, as injections are required for current FDA-approved versions.

Combining GLP-1 receptor agonists (Liraglutide or Exenatide) with Metformin significantly improves pregnancy rates and endometrial receptivity compared to Metformin monotherapy in women with PCOS undergoing IVF.

If you have PCOS, are overweight, and are struggling with infertility despite trying standard treatments like Clomiphene, ask your doctor about adding Liraglutide to your Metformin regimen before starting IVF. One study showed this combination significantly improved pregnancy rates per embryo transfer compared to Metformin alone. Note that these drugs are not approved for use during pregnancy, so a washout period is required.

Sustained remission of type 2 diabetes (via weight loss or bariatric surgery) reduces the risk of microvascular and macrovascular complications compared to standard care.

Achieving remission through sustained weight loss or surgery not only normalizes blood sugar but also significantly reduces your risk of heart disease, kidney damage, and eye problems over the long term. This benefit is likely greater than just controlling blood sugar with medication alone.

Current standard-of-care obesity treatments (lifestyle, pharmacotherapy, surgery) exhibit high variability in weight loss outcomes, necessitating a precision medicine approach based on biological markers to predict individual response.

Standard obesity treatments (diet, drugs, surgery) do not work equally for everyone. The paper argues that future care will use biological markers (genetics, microbiome, etc.) to predict who will respond to which treatment, moving away from a 'one-size-fits-all' BMI-based approach.

Gut microbiota composition influences energy metabolism and food intake, and specific microbial signatures may predict response to dietary interventions and bariatric surgery.

Your gut bacteria play a role in how your body processes food and regulates energy. While specific 'microbiome diets' are not yet proven, dietary changes and bariatric surgery can positively alter microbiome diversity, which may contribute to weight loss and metabolic health.

Higher dietary intake of polyunsaturated fatty acids (PUFAs) is associated with a lower risk of heart disease mortality in adults without prior myocardial infarction, whereas saturated (SFAs) and monounsaturated fatty acids (MUFAs) show no such association.

For heart health prevention, focus on increasing polyunsaturated fats (found in fish, nuts, seeds, and vegetable oils) rather than just cutting saturated fats. This benefit appears strongest for people who have not yet had a heart attack. If you have existing heart disease, dietary changes alone may not be sufficient to reduce mortality risk, and medical management is critical.

Liraglutide treatment is associated with decreased liver fibrosis in patients with type 2 diabetes, as evidenced by lower NAFLD fibrosis score (NFS), FIB-4, and liver stiffness measurement (LSM) after 12 months.

If you have Type 2 Diabetes, ask your doctor about Liraglutide. This medication has been shown to be associated with reduced markers of liver scarring (fibrosis) over a year of use. This is particularly relevant if you are at risk for Non-Alcoholic Fatty Liver Disease (NAFLD), which is common in T2DM. The benefit appears to be linked to its hormonal effects and weight loss.

Once-weekly subcutaneous semaglutide (up to 1.0 mg) in patients with type 2 diabetes produces significant weight loss (-4.69 kg at 6 months, -5.38 kg at 12 months) and improves metabolic parameters, but this weight loss is accompanied by a significant reduction in lean body mass (over 3 kg) that requires mitigation through nutritional education and structured exercise.

If you are using once-weekly semaglutide for Type 2 Diabetes, expect to lose about 5 kg of body weight over 6-12 months, along with improvements in blood sugar and blood pressure. However, this weight loss includes a significant loss of muscle mass (over 3 kg). To counteract this, you must actively engage in resistance exercise and follow a nutrition plan that prioritizes protein, as the medication alone will not preserve your muscle.

Patients using GLP-1 receptor agonists (GLP-1RA) for weight loss consistently fail to meet Dietary Reference Intakes (DRI) for key micronutrients (fiber, calcium, iron, magnesium, potassium, choline, vitamins A, C, D, E, K) and MyPlate food group servings (fruit, vegetables, grains, dairy).

If you are taking a GLP-1RA, your reduced appetite likely means you are not getting enough fiber, calcium, magnesium, and vitamins. You must actively track your food intake to ensure you are hitting micronutrient goals, as you cannot rely on feeling full. Focus on nutrient-dense foods and consider supplementation if dietary intake remains low, as standard portion sizes are likely insufficient.

GLP-1RA users often underconsume protein relative to their increased needs for preserving lean mass during rapid weight loss, despite protein percentage of calories being within the Acceptable Macronutrient Distribution Range (AMDR).

Even if your protein percentage looks fine, you are likely not eating enough grams of protein to protect your muscles while losing weight rapidly on GLP-1RA. Aim for 1.2-2.0 g of protein per kg of body weight daily. Prioritize lean protein sources in every small meal.

High Body Mass Index (BMI) is the leading risk factor for T2DM-related mortality globally, particularly in Low- and Middle-Income Countries, although trends in High-Income Countries showed a decrease between 2005 and 2015.

Maintain a healthy body weight, as high BMI is the leading risk factor for T2DM mortality worldwide. This is especially critical if you live in a middle- or low-income country where obesity rates are rising. While BMI isn't perfect, managing your weight through diet and activity is the most impactful step you can take to reduce your diabetes risk.

For resistance-trained individuals, a moderate protein intake of 1.8 g/kg/day is sufficient for recovery and performance maintenance during repeated intensive training, as a high intake of 2.9 g/kg/day provides no additional benefit when peri-exercise protein timing is controlled.

If you are a regular strength trainer, aim for 1.8 grams of protein per kilogram of body weight daily. You do not need to push this to 2.9 g/kg for better recovery, especially if you are consuming protein around your workouts. Focus on hitting the 1.8 g/kg target consistently rather than over-consuming.

Initiating anti-obesity medications (AOMs) at the weight loss plateau (WLP) is more effective for achieving additional weight loss than waiting until significant weight regain occurs.

Do not wait for significant weight regain to seek help. If your weight stops dropping after surgery (plateau), discuss starting an anti-obesity medication immediately to maximize your results.

A combined nutraceutical product containing Lagerstroemia speciosa, Berberis aristata, Curcuma longa, Alpha-lipoic acid, Chromium picolinate, and Folic acid significantly improves triglycerides, HDL-C, fasting plasma insulin, and HOMA-Index in patients with impaired fasting glucose over an 8-week period.

If you have impaired fasting glucose, a specific combination of plant extracts and micronutrients (Banaba, Berberine, Turmeric, Alpha-lipoic acid, Chromium, Folic acid) taken as two pills daily for 8 weeks, alongside standard dietary and exercise advice, may significantly improve your triglycerides, HDL cholesterol, and insulin resistance markers compared to placebo. This suggests it could be a useful tool for managing metabolic risk in pre-diabetic individuals, though long-term effects are not yet established.

Precision nutrition, which tailors dietary interventions to individual genetic backgrounds, gut microbiota, and metabolic profiles, has the potential to transform obesity management by addressing interindividual variability in weight loss responses.

Instead of following generic diet advice that may not work for you, consider approaches that look at your specific body metrics, genetics, or gut health. While full genetic testing isn't always necessary or affordable, using metabolic profiles or simple clustering can help tailor your diet for better weight loss results. The key is personalization: what works for one person might not work for you, so finding a method that fits your unique biology is crucial for long-term success.

Partial ROM training performed at long muscle lengths (e.g., bottom half of a squat) may produce greater muscle hypertrophy than full ROM training.

If you are doing partial reps, ensure you are doing them at long muscle lengths (e.g., the bottom half of a squat). This specific variation may actually build muscle slightly better than full squats. Avoid partial reps at short muscle lengths (e.g., top half of a squat) if hypertrophy is your goal, as they offer no advantage over full ROM.

Dietary fibers, particularly soluble apple pectin, selectively reshape the gut microbiota of obese individuals by increasing beneficial bacteria (Megasphaera, Akkermansia) and reducing harmful ones (Acidaminococcus intestini), thereby improving metabolic health markers compared to lean profiles.

If you are obese, not all fibers are created equal for your gut health. Soluble fibers like apple pectin appear to specifically boost beneficial bacteria (like Akkermansia and Megasphaera) and reduce harmful ones in obese gut environments. Incorporating apple pectin or whole apples may be a more effective strategy for metabolic health than generic fiber supplements.

Low-carbohydrate diets can lead to micronutrient deficiencies, including thiamine, folate, vitamin C, magnesium, calcium, iron, and iodine, due to the avoidance of whole grains, fruits, and starchy vegetables.

If you are on a low-carb diet, ensure you are getting enough micronutrients by eating low-carb vegetables (like leafy greens) or considering supplementation, especially for thiamine, folate, and magnesium.

High intake of added fructose (from processed foods/beverages) is significantly associated with increased odds of metabolic syndrome in healthy adults, whereas high intake of natural fructose (from fruits/vegetables) is not.

Distinguish between your sources of sugar. The study links high intake of added fructose (found in processed foods and sweetened beverages) to a significantly higher risk of metabolic syndrome. However, high intake of natural fructose from whole foods like fruits and vegetables was not associated with this risk. Prioritize reducing added sugars from industrialized foods while maintaining fruit and vegetable intake.

Recreational athletes can maintain endurance and muscular strength performance on predominantly plant-based diets (whole food or meat alternatives) compared to an omnivorous diet, provided protein and carbohydrate intake meet standard sports nutrition recommendations.

If you are a recreational athlete, you do not need to eat meat to maintain your running speed or strength. You can switch to a whole-food plant-based diet or use plant-based meat alternatives (like Beyond or Impossible burgers) as long as you eat enough protein (0.8-1.2g/kg/day) and carbohydrates (3-5g/kg/day). Ensure you are eating enough total calories and maintaining your training routine.